In this context, EZM0414, a clinical-grade SETD2 inhibitor, was being evaluated in a Phase I clinical trial as a therapeutic in relapsed or refractory multiple myeloma and diffuse large B cell lymphoma, suggesting that at least in these cancer types, H3K36me3 generation may be oncogenic (NCT05121103; note this trial was terminated). This evidence concerns the gene SETD2 and plasma cell myeloma.